Glioma prognostic marker circ1:246186743|246186942 and its application

A glioma and prognosis technology, applied in biochemical equipment and methods, microbial determination/examination, DNA/RNA fragments, etc., can solve the problems of unsatisfactory curative effect and easy recurrence.

Active Publication Date: 2020-09-11
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For the treatment of glioma, surgery is still the most important method traditionally, but because gliomas are mostly infiltrating growth, after simple surgery, it is easy to relapse, and the curative effect is not satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glioma prognostic marker circ1:246186743|246186942 and its application
  • Glioma prognostic marker circ1:246186743|246186942 and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1: Preparation of circRNA circ1:246186743|246186942 kit for the prognosis of glioma patients (50 reactions)

[0017] 1. RNA stabilization solution 50ml

[0018] 2. Isopropanol 100ml

[0019] 3. Chloroform 100ml

[0020] 4. Trizol 50ml

[0021] 5. Enzyme-free water 10ml

[0022] 6.1 μM random reverse transcription primer 50 μl

[0023] 7.5× reverse transcription buffer 200ml

[0024] 8. 10mM base triphosphate deoxynucleotides 100μl

[0025] 9.40U / μl RNase inhibitor 500μl

[0026] 10.200U / μl MMLV reverse transcriptase 50μl

[0027] 11.Premix Ex Taq 50μl

[0028] 12.10μM circRNA circ1:246186743|246186942 real-time fluorescence quantitative PCR specific primer 30μl

[0029] Forward primer: 5'-CACGACTTGGCTGAGGAA-3',

[0030] Reverse primer: 5'-CCCCACATCACAGGCACA-3'.

[0031] 13.10 μM GAPDH specific primer 30 μl

[0032] The forward primer is 5′-ATCATCAGCAATGCCTCCT-3′,

[0033] The reverse primer was 5'-CATCACGCCACAGTTTCC-3'.

Embodiment 2

[0034] Example 2: The relationship between the expression level of circRNA circ1:246186743|246186942 in glioma tissue and prognosis

[0035] 1. Collect the glioma tissue to be tested, put it into a cryopreservation tube filled with RNA stabilization solution, and put it in a -80°C refrigerator for later use.

[0036] 2. Extraction of RNA in tissues: Take an appropriate amount of specimen, add liquid nitrogen to the mortar after baking at 180°C for 6-8 hours, grind the specimen, grind it to powder, add 1ml Trizol mortar specimen in the mortar, and grind it into After the liquid was transferred to a tube, it was lysed on ice for 15 minutes. After the lysis, centrifuge at 12000rpm for 10min at 4°C, and transfer the supernatant to a new tube. Add 200 μl of chloroform to the tube, shake it by hand for 15-30 seconds, place it on ice for 5 minutes, centrifuge at 12000 rpm for 15 minutes at 4°C; carefully take the upper layer of the aqueous phase into a new tube, add 0.5ml of pre-coo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a glioma prognostic marker circ1:246186743|246186942 and application. A reagent for detecting circRNA circ1:246186743|246186942 of a glioma source is used for preparing a prognostic preparation of a glioma patient. Research proves that the glioma patient with relatively high expression of circRNA circ1:246186743|246186942 has relatively poor postoperative survival rate. A prognosis of the glioma patient is made by detecting the expression level of circ1:246186743|246186942 in glioma tissue of the glioma patient.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to a circRNA marker for glioma prognosis, the application of a reagent for detecting the marker to prepare a glioma prognosis preparation, and a kit. Background technique [0002] Glioma is the most common malignant tumor in the brain, the incidence of glioma in China accounts for 35% to 60% of intracranial tumors, and the 5-year survival rate is only 20% to 30%. One of the most serious tumors faced. Traditionally, surgery is still the most important method for the treatment of glioma, but because most of the glioma grows infiltrating, it is easy to relapse after simple surgery, and the curative effect is not satisfactory. Therefore, it is an urgent research task in the field of neuroscience to find glioma prognostic markers to analyze the prognosis of patients, so as to improve the postoperative survival period of glioma patients and choose a reasonable follow-up treatment accordingly. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886C12N15/113
CPCC12Q1/6886C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 刘长红武明花李沛瑶刘庆王蓉刘强陈琼
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap